Novartis and Celgene get EU approval for novel psoriasis therapies
This article was originally published in Scrip
Executive Summary
The European Commission has approved two new drugs for psoriasis: Novartis's Cosentyx (secukinumab) and Celgene's Otezla (apremilast).
You may also be interested in...
Novartis Pursues Disease-Modifying Differentiator For Cosentyx In Psoriasis
New extension data suggesting that Novartis's IL-17A inhibitor Cosentyx could alter the course of disease in its lead indication of psoriasis could position the drug earlier in the treatment paradigm and please payers; the company has launched a new prospective study to see if the results hold true.
Celgene’s Otezla Gets Preliminary Nod From NICE At Second Attempt
Celgene’s near-blockbuster oral psoriasis drug Otezla is cleared by NICE in a second draft guidance for use in severe psoriasis, after the company comes up with an acceptable patient access scheme.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.